India Glycols Ltd (INDIAGLYCO) — Announcement | 2 September 2026(3 announcements)

India Glycols Limited announced its investor presentation for an analyst meeting scheduled on September 2, 2026, focusing on its nutraceutical and botanical ingredients business under the Ennature Biopharma platform. The filing highlights structural growth trends in global health supplements, expansion of branded ingredients, and strategic initiatives to scale high-value products. It underscores the company's shift toward clinically validated, science-driven nutraceutical solutions with global regulatory certifications and export reach across 26+ countries. The presentation emphasizes future growth through innovation, market expansion, and leveraging legacy expertise in green chemistry.

India Glycols Limited (IGL) presented its investor outlook for IGL Spirits, highlighting robust growth in the Potable Spirits segment with 13% revenue increase and 100%+ growth in Bio-Fuels, driven by premiumization, strategic partnerships like Amrut, and expansion into CSD and paramilitary channels. The presentation emphasized scalable manufacturing capacity, strong margins, and a clear pathway to INR 1,000 Crore EBITDA by FY27 through integrated operations and ethanol demand tailwinds.

India Glycols disclosed a revised investor presentation after correcting a typographical error in the version submitted on September 2, 2026. The filing confirms the demerger of its Spirits, Biofuels, and Biopharma businesses into three independently listed entities, effective September 1, 2026, with shareholders receiving shares in the new companies. The presentation highlights financial growth, sustainability initiatives, and future strategic blocks focused on renewable chemistry. It emphasizes operational strengths, including rail-linked logistics and global partnerships, while outlining aspirations for revenue and EBITDA expansion over the next decade.